Telix spotlights Phase 3 IPAX BrIGHT trial of TLX101 — Tx in recurrent glioblastoma at EANM congress
Telix flagged multiple late-stage oncology readouts slated for the Oct. 17-21 European nuclear medicine congress in Vienna. Topline Phase 3 data for Illuccix prostate cancer PET imaging in Chinese men will be presented, positioning the product for broader commercialization. Interim results will be presented for TLX597-Tx in metastatic castration-resistant prostate cancer, supporting development of a next-generation PSMA therapy. Phase 3 programs in recurrent glioblastoma (TLX101-Tx) and clear cell renal cell carcinoma (TLX250-Tx) were highlighted as pivotal value drivers. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via (Ref. ID: 202610140100PR_NEWS_EURO_ND__EN71537) on October 14, 2026, and is solely responsible for the information contained therein. (C)
Telix flagged multiple late-stage oncology readouts slated for the Oct. 17-21 European nuclear medicine congress in Vienna. Topline Phase 3 data for Illuccix prostate cancer PET imaging in Chinese men will be presented, positioning the product for broader commercialization. Interim results will be presented for TLX597-Tx in metastatic castration-resistant prostate cancer, supporting development of a next-generation PSMA therapy.
Phase 3 programs in recurrent glioblastoma (TLX101-Tx) and clear cell renal cell carcinoma (TLX250-Tx) were highlighted as pivotal value drivers. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd.
published the original content used to generate this news brief via (Ref. ID: 202610140100PR_NEWS_EURO_ND__EN71537) on October 14, 2026, and is solely responsible for the information contained therein. (C)